mRNA Vaccines – Trials Line Up Against Coronavirus
New Technology Attracts Attention
Executive Summary
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
You may also be interested in...
Finance Watch: Sana Reveals Cash Haul Of $700m In Under Two Years
Private Company Edition: The allogeneic cell therapy developer founded by former Juno execs launched in January 2019 without disclosing its initial funding. Other recent venture capital mega-rounds include $192m for Orca, $170m for C4, $118m for Shattuck and $102m for GreenLight.
Biocad To Launch Two Biosimilars In Bosnia-Herzegovina
Russia’s Biocad, with biosimilars already launched in numerous global markets, is continuing to look outward. A focus on territories in south-east Europe has seen the firm receive approvals for two biosimilars in the Balkan country Bosnia and Herzegovina.
CureVac Denies Takeover Reports As It Slates Phase I Coronavirus Vaccine Study For Early Summer
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.